Join to View Full Profile
619 19th St SBirmingham, AL 35233
Phone+1 205-934-6600
Fax+1 205-978-4346
Dr. Conry is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1993- University of Alabama Medical CenterResidency, Internal Medicine, 1987 - 1990
University of Alabama School of MedicineClass of 1987
Certifications & Licensure
AL State Medical License 1988 - 2025
FL State Medical License 2021 - 2023
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Vaccine Therapy in Treating Patients With Melanoma Start of enrollment: 1999 Jan 01
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 12
Publications & Presentations
PubMed
- 182 citationsCombination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, Ahmad A Tarhini, Gary I Cohen
Journal of Clinical Oncology. 2023-01-10 - 38 citationsAdjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma.Kenneth F. Grossmann, Megan Othus, Sapna Pradyuman Patel, Ahmad A. Tarhini, Vernon K. Sondak
Cancer Discovery. 2021-11-11 - 81 citationsNeoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trialReinhard Dummer, David E. Gyorki, John R. Hyngstrom, Adam C. Berger, Robert M. Conry
Nature Medicine. 2021-10-04
Journal Articles
- E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High Dose Interferon-α2b in Advanced MelanomaArun Nagarajan, Mark R Albertini, Stuart Wong, Noel Laudi, Robert M Conry, Clinical Cancer Research
Press Mentions
Team of UAB Doctors Performs New Procedure for Rare GI MelanomaMarch 30th, 2021
Grant Support
- Polynucleotide Vaccine Therapy Of Breast CancerNational Cancer Institute2000–2002
- Polynucleotide Vaccine Strategies For MelanomaNational Cancer Institute1999–2002
- Trial Of Antiidiotypic MAB Vaccine 4b5 In MelanomaNational Center For Research Resources2000
- Immunization Of Colorectal Cancer Patients With Oncovax-ClbNational Center For Research Resources2000
- Poylnucleotide Anti Tumor Immunization To Human CEA In Metastic Colorectal CancerNational Center For Research Resources1998–2000
- Alvac Hil2 Intratumorally In Surgically Incurable MelanomaNational Center For Research Resources1998–2000
- Recobinant Vaccinia CEA Delivery In Metastatic CEA Expressing AdenocarcinomaNational Center For Research Resources1998–1999
- Polynucleotide Immunization For Therapy Of Breast CancerNational Cancer Institute1997–1999
- Polynucleotide Vaccines For Colon Cancer And MelanomaNational Cancer Institute1995–1998
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
